Drug Profile
RGRN 305
Alternative Names: BEBT-305; CU-0305; CUDC-305; DEBIO 0932; Debio-0932; MC2-32; RGRN-305Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Curis
- Developer Curis; Debiopharm; MC2 Therapeutics; Regranion
- Class 2 ring heterocyclic compounds; Anti-inflammatories; Antipsoriatics; Benzodioxoles; Imidazoles; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Phase I Plaque psoriasis
- Phase Unknown Atopic dermatitis; Bullous pemphigoid
- Discontinued Cancer; Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 11 Oct 2023 Phase-II clinical trials in Hidradenitis suppurativa in Denmark (PO) before October 2023
- 11 Oct 2023 MC2 Therapeutics plans a phase IIb trial for Hidradenitis suppurativa
- 11 Oct 2023 Efficacy and adverse events data from a phase I trial in Hidradenitis suppurativa released by MC2 Therapeutics